Sepantronium Bromide (PC-002)
Cothera’s lead program PC-002 is a first-in-class small molecule drug targeting Myc-mutated tumors. With more than 50% of human cancers showing increased expression, Myc is regarded as one of the most important yet “undruggable” cancer targets. With a unique mechanism of action, PC-002 selectively induces Myc protein degradation and cell apoptosis in Myc-dependent tumors, potentially targeting multiple indications in cancers involving Myc dysregulation.
PC-002 program is currently in Phase 2 clinical studies for multiple indications, including high-grade lymphoma in patients with c-MYC translocation (NCT05263583) as well as neuroendocrine prostate cancer in patients with n-MYC abnormality.